Analytical and clinical performance of a Chikungunya qRT-PCR for Central and South America by Adams, Emily
Diagnostic Microbiology and Infectious Disease xxx (2017) xxx–xxx
Contents lists available at ScienceDirect
Diagnostic Microbiology and Infectious Disease
j ourna l homepage: www.e lsev ie r .com/ locate /d iagmicrob ioAnalytical and clinical performance of a Chikungunya qRT-PCR for
Central and South America☆,☆☆Thomas Edwards a,⁎, Leticia del Carmen Castillo Signor b, Christopher Williams a, Clément Larcher c,
Mauricio Espinel d, Jane Theaker c,1, Evelin Donis b, Luis E. Cuevas a, Emily R. Adams a
a Research Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK
b Laboratorio Nacional de Salud Guatemala, Ministerio de Salud Publica y Asistencia Social de Guatemala, Villa Nueva, Guatemala
c QIAGEN Manchester Ltd, Skelton House, Lloyd Street North, Manchester, UK
d Universidad San Francisco de Quito, Quito, Ecuador
a b s t r a c ta r t i c l e i n f o☆ Sources of funding: The study was funded through t
award numberMC-PC_14111. The funders had no role in t
lection, analysis or preparation of the manuscript.
☆☆ Conﬂicts of interest statement: Clément Larcher is em
Ltd, a commercial company producing diagnostics. QIAGE
for RNA extraction for the project and loaned an RGQ 600
⁎ Corresponding author. Tel.: +44-7791160768.
E-mail addresses: Thomas.Edwards@lstmed.ac.uk (T. E
Castillo.leticia@lns.gob.gt (L. del Carmen Castillo Signor), C
(C. Williams), Clement.Larcher@QIAGEN.com (C. Larcher)
(M. Espinel), Jane.Theaker@LGCgroup.com (J. Theaker), Don
Luis.Cuevas@lstmed.ac.uk (L.E. Cuevas), Emily.Adams@lstm
1 Current address; LGC, DarwinHouse, Faraday Street, B
UK.
http://dx.doi.org/10.1016/j.diagmicrobio.2017.06.001
0732-8893/© 2017 The Authors. Published by Elsevier Inc
Please cite this article as: Edwards T, et al, A
Microbiol Infect Dis (2017), http://dx.doi.orgArticle history:
Received 8 December 2016
Received in revised form 1 June 2017
Accepted 3 June 2017
Available online xxxx
Keywords:
Diagnostics
Chikungunya
Arboviruses
Molecular diagnostics,Chikungunya was introduced into the Americas in 2015 causing a pandemic across the continent. Testing during
the acute phase of infection relies on qRT-PCR, but available assays have a number of limitations. A qRT-PCR assay
speciﬁc to the chikungunya E1 genewas designed using sequence data from contemporary strains. A probit anal-
ysis established the 95% limit of detection as 19.6 copies per reaction. We compared the assay with a US Centers
for Disease Control (CDC) chikungunya qRT-PCR as the reference standard. The assay had a sensitivity and spec-
iﬁcity of 98.4% and 100% in 90 samples retrospectively collected inGuatemala. In a further 74 febrile samples pro-
spectively collected in Ecuador and Guatemala the test had a sensitivity and speciﬁcity of 100% and 98.4%,
respectively. Sequencing the nsp4 gene of the discordant positive sample indicated the presence of chikungunya
RNA, and mismatches to the primer binding sites of the CDC assay.he MRC C
he design
ployed b
N, Germ
0.
dwards)
hris.Wil
, mespine
is.evelin@
ed.ac.uk (
irchwood
. This is a
nalytica
/10.10© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Chikungunya virus (CHIKV), an alphavirus transmitted by Aedes
mosquitoes, causes an acute febrile illness with a wide range of symp-
toms including fever, rash, and headache. Severe polyarthralgia occurs
in up to 95% of cases (Weaver and Lecuit, 2015), which can progress
to chronic polyarthritis in around 5% of patients (Ganu andGanu, 2011).
In 2013, the Asian lineage of the CHIKV strain was reported in the is-
land of St. Martin in the Americas. Initial reports were followed by a
rapid spread across the Caribbean, causing over 790,000 cases.onﬁdence in Concept
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16/j.diagmicrobio.2017Despite being a major pandemic (Cugola et al., 2016), only about 4%
of the cases occurring in 2015 were conﬁrmed by laboratory tests. The
lack of conﬁrmation hinders the accuracy of epidemiological data, as
dengue (DENV) and Zika share the same vectors, are hyperendemic in
the region and have similar clinical presentation.
Distinguishing acute DENV, Zika and CHIKV is important due to their
potential complications. DENV can progress to severe dengue, charac-
terized by hemorrhages and shock; Zika is associated with congenital
and neurological anomalies which require an early diagnosis during
pregnancy (Cao-Lormeau et al., n.d.; Cugola et al., 2016), while CHIKV
often leads to debilitating polyarthritis.
Themethods available for CHIKVdiagnosis dependonhowmanydays
the patient has been symptomatic. Enzyme Link Immuno-assays (ELISA)
can detect Immunoglobulin (Ig) M antibodies after 5 days of symptoms
and a raise of Ig G antibody titres can conﬁrm the infections if paired sam-
ples are available (Prince et al., 2015). However ELISAs are unable to con-
ﬁrm infections between days 1–5 of symptoms (Yap et al., 2010).
CHIKV viraemia is present in the ﬁrst 5–7 days of symptoms and
RNA can be detected in serum or whole blood using molecular assays;
usually using reverse transcriptase polymerase chain reaction (qRT-
PCR). A number of qRT-PCR assays are commercially available, which
are typically able to detect between 4 and 20 gene copies per reaction
(Edwards et al., 2007; Panning et al., 2009; Pongsiri et al., 2012).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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been designed (Cecilia et al., 2015; Waggoner et al., 2016) and a high
throughput transcription-mediated ampliﬁcation assay to screen
asymptomatic blood donors is under development (Charles et al., 2015).
A frequently used qRT-PCR assaywas developed by theUS Centers of
Disease Control and Prevention (CDC) in 2007 (Lanciotti et al., 2007),
and is often considered the reference standard for CHIKV diagnosis.
The assay was designed prior to the American pandemic, and therefore
may not have incorporated contemporary strains, which could poten-
tially reduce sensitivity.
We report here the design and validation of a qRT-PCR assay capable
of detecting all lineages of CHIKV, which contains an internal control to
identify sample inhibition. The assay is speciﬁc to a highly conserved re-
gion of the E1 gene and is suitable for laboratories capable of performing
qRT-PCR.
2. Methods
2.1. Ethics statement
Samples obtained from Guatemala were anonymised samples sub-
mitted to the national reference surveillance laboratory (Laboratorio
Nacional de Salud, LNS) for surveillance and diagnostic purposes. Sam-
ples were obtained with patients' consent and donated to the laborato-
ries to conduct further testing and assay evaluation. The collection of
samples fromEsmeraldas, Ecuador was approved by the ethics commit-
tee of San Francisco de Quito University, Ecuador. The results of the
study were anonymised and were not used for clinical management
or surveillance purposes.
2.2. The study
A qRT-PCRwas designed based upon contemporary CHIKV sequence
data and underwent an analytical evaluation, followed by a ﬁeld evalu-
ation. We evaluated its limits of detection (LOD), linearity and repro-
ducibility using RNA extracted from cultured virus, which was
quantiﬁed via qRT-PCR. The assay was then compared to the CDC
assay using a retrospective sample collection of 90 samples which
were CHIKV CDC qRT-PCR positive and CHIKV-negative at the LNS in
Guatemala and 74 prospectively collected febrile serum samples from
Ecuador (n = 63) and Guatemala (n = 11).
2.3. Assay design
The primers and probe for the CHIKV E1 assay were designed to en-
sure maximum sequence complementarity with a wide range of strains
from all geographical areas. Sequence alignments were carried out
using ClustalW involving 100 geographically diverse CHIKV genomes
and full and partial E1 gene sequences (North America [n = 4], Central
America [n= 10], South America [n= 28], Caribbean [n= 17], Europe
[n= 1], Africa [n= 15], Asia [n= 22], Oceania [n= 3],) retrieved from
GenBank. The sequence alignments were carried out in the summer of
2015. Primer and probes were designed using Primer3, with binding
sites selected tominimize the number ofmismatches. Candidate primer
and probe sets were checked for cross-reactivity using BLAST, and for
secondary structure and self-complementarity using Mfold and
OligoCalc. In adherence toMIQE guidelines (Bustin et al., 2011), we pro-
vide a PCR amplicon context sequence; the anchor nucleotide is at posi-
tion 100,450, and the amplicon context sequence ranges from 100,390
and 100,523 (positions based on reference sequence NC 004612).
2.4. Viral culture
Viral stocks of the ECSA CHIKV Ross strain were produced using Ae.
albopictus C6/36 cells infected at a multiplicity of infection (MOI) of
0.1 PFU (plaque forming units)/cell for 48 h at 27 °C. Stocks werePlease cite this article as: Edwards T, et al, Analytical and clinical perform
Microbiol Infect Dis (2017), http://dx.doi.org/10.1016/j.diagmicrobio.2017constituted after two passages on C6/36 cells, titrated on Vero cells,
and stored at -20 °C until use.
2.5. RNA extraction
RNA extractionswere carried out from clinical samples and viral cul-
tures using the QIAGEN Viral RNA extraction kit (QIAGEN, UK). The ex-
tractions required a 120 μl aliquot of the serum sample and eluted in
60 μl of elution buffer following the manufacturer's instructions.
2.6. CHIKV qRT-PCR assay
The CHIKV qRT-PCR assays were set up as follows, using reagents
supplied with the QuantiFast Pathogen qRT-PCR + IC kit (QIAGEN,
UK); 5 μl 5× QuantiFast pathogen master mix, 0.25 μl 100× QuantiFast
Pathogen RT mix, 2.5 μl 10× internal control assay, 2.5 μl 10× internal
control RNA, 0.4 μM E1 forward primer, 0.4 μM E1 reverse primer,
0.2 μM E1 probe, and 5 μl of template RNA or H2O no-template control
in a total volume of 25 μ. The reactionswere as follows; activation of re-
verse transcription at 50 °C for 20 minutes, followed by 95 °C for
5 minutes, and then 45 cycles of denaturation at 95 °C for 15 seconds,
and extension at 60 °C for 30 seconds.
The CHIKV qRT-PCR assays were analyzed using a Rotor-gene Q sys-
tem (QIAGEN, UK). A cut-off value of Ct 37 was chosen to allow direct
comparison with the CDC reference assay, which utilizes this cut off.
The threshold level was determined as being 0.13 during the investiga-
tion of assay reproducibility, as described below.
2.7. CDC qRT-PCR reference assay
Weused a CHIKVqRT-PCR designed by theDiagnostic and Reference
Laboratory, Arbovirus Diseases Branch, CDC, using the 6856F/6981c/
6919-FAM primer set for the nsp4 gene as the reference assay
(Lanciotti et al., 2007). The PCR reactions contained 12.5 μl Invitrogen
SuperScript iii one-step 2× reaction mix, 0.5 μl SuperScript iii RT/Plati-
num Taq enzyme mix, 0.4 μM of each primer, 0.2 μM 6919-FAM probe,
and 5 μl of template RNA. Sufﬁcient molecular grade water was then
added to produce a ﬁnal reaction volume of 25 μl. The reactions were
monitored using a Rotorgene Q (QIAGEN, UK).
The reaction parameters were as follows; reverse transcription at
50 °C for 30 minutes, followed by 95 °C for 2 minutes, and then
45 cycles of denaturation at 95 °C for 15 seconds, and extension at
60 °C for 30 seconds.
2.8. Plasmid generation and quantitation
A DNA plasmid containing the CHIKV amplicon was used as a quan-
tiﬁable stock of the assay target, for determining CHIKV RNA concentra-
tion via a standard curve. A 3817 bp double stranded DNA plasmid
containing the CHIKV assay amplicon was obtained commercially
from Oxford Genetics Ltd. (UK). The plasmid concentrationwas quanti-
ﬁed using a Qubit 3.0 ﬂuorometer (ThermoFisher, UK).
2.9. Sequencing
Serum samples (n = 8) were selected for sequencing of both the
nsp4 and E1 genes, to examine for variation in the primer binding
sites of both the index and reference tests. The samples included one
with discordant test results fromGuatemala, and also sampleswith con-
cordant results sourced from Guatemala (n = 5) and Ecuador (n = 2).
All samples chosenwere bCt 30 in order to ensure sufﬁcient RNA for the
sequencing methodology. Reverse transcription was conducted using
the Superscript IV reverse strand synthesis system (Invitrogen, UK), fol-
lowing the manufacturer's instructions. The resulting cDNA from each
sample was ampliﬁed by PCR using the E1 and nsp4 primer sets, using
the proof reading Phusion high ﬁdelity DNA polymerase reaction mixance of a Chikungunya qRT-PCR for Central and South America, Diagn
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Fig. 1. Linear range of the CHIKV E1 RT-PCR assay.
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quences for ampliﬁcation of a 1320 bp fragment of the E1 gene (posi-
tions 9991–11,310) were taken from (Shrinet et al., 2012) (E1-gene-F
and E1-gene-R primers). Primers for the ampliﬁcation of a 763 bp re-
gion of the nsp4 gene (6732F and 7495R) were taken from
(Schuffenecker et al., 2006). Cycling parameters for PCR reactions con-
taining both sets of primers were as described (Nunes et al., 2015).
PCR amplicons were puriﬁed using a QIAquick PCR puriﬁcation kit
(QIAGEN, UK), following the manufacturer's instructions. The forward
and reverse strand of puriﬁed ampliconswere sequenced commercially
at Source Bioscience (UK), using the same primers.
2.10. Assay characteristics
The linearity of the assay was determined by testing eight sequential
1:10 dilutions of CHIKV RNA, in ﬁve replicates. A line of best ﬁt was ﬁtted
via regression analysis on a plot of the Ct value (y-axis) and log concentra-
tion (x-axis). The portion of the line that maintained an R2 value of over
0.99 was regarded as indicating the linear range of the assay.
2.11. Reproducibility
The inter and intra-assay coefﬁcient of variation (CV)was calculated
as a measure of reproducibility and was determined using three 1:100
dilutions of CHIKV RNA. Concentrations of 1 × 107, 1 × 105 and 1
× 103 per reaction were chosen to represent a high, medium and low
quantity of RNA over the linear range of the assay. Each dilution was
assayed using the CHIKV qRT-PCR in triplicate, and the experiment
was repeated ﬁve times over consecutive days by the same operator,
using the same batch of reagents. Average baseline and maximum ﬂuo-
rescence values were collected from these experiments and averaged to
determine the Ct calling. The threshold was set at the value of the base-
line ﬂuorescence plus 10% of the difference between the baseline and
maximum ﬂuorescence. This value was determined to be 0.13, and
this level was used for all assays, including previous assays, which
were reanalysed accordingly.
2.12. LOD
The LOD was determined by testing RNA dilutions of a known con-
centration. Viral RNA extracted from culture was quantiﬁed via a stan-
dard curve consisting of dilutions of the amplicon containing plasmid.
This RNAwas then diluted to give 1 × 108 copies per reaction, and dilut-
ed sequentially to a concentration giving 1 copy per reaction. A total of
ﬁve reactions were conducted per dilution. Further experiments were
conducted testing 100, 75, 50, 25, 15 and 10 copies, with ﬁve reactions
per dilution. Data was analyzed using a probit regression analysis to cal-
culate the 95% and 50% LOD.
2.13. Speciﬁcity
The CHIKV qRT-PCR was challenged with 0.1 μg of genomic RNA for
DENV serotypes 1 (Strain TC974), 2 (Strain R062), 3 (Strain H87), 4
(Strain TC1000), Inﬂuenza A H3N2 virus (Strain A/Wuhan/359/95), In-
ﬂuenza B (Strain B/Brisbane), measles (Strain Mvs/London.GBR/
25.07), Yellow fever (French Neurotropic strain), Mayaro virus (Strain
TC652) and Zika virus (Brazilian epidemic strain). Additionally the
assay was tested using 48 RNA samples submitted to LNS in 2015 con-
ﬁrmed as being positive for DENV using the CDC DENV 1–4 qRT-PCR
assay (26), and negative by the CDC CHIKV qRT-PCR assay. The samples
included DENV1 (3), DENV2 (38), DENV3 (3) and DENV4 (4).
2.14. Bank sample collection
Stored serum samples kept at−80 °C for between 1 and 4 weeks at
the LNS were used as alpha evaluation samples in clinical specimens.Please cite this article as: Edwards T, et al, Analytical and clinical perform
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negative samples. After RNA extraction, all samples were tested in the
UK using the CDC CHIKV and our CHIKV qRT-PCR assays using the
Rotorgene Q.
2.15. Prospective sample collection
Serum samples were obtained from 63 patients presenting at a fever
clinic in Hospital Delﬁna Torres Conchan in Esmeraldas, Ecuador, in July
2015with symptoms b10 days duration. All eligible patients presenting
over 3 days were included in the study. Of these, 10 patients had symp-
toms for b1 day; 16 for 2 days, 13 for 3 days, 6 for 4 days, 10 for 5 days, 1
for 6 days and 2 for 7 days. Their median age was 20 years with a range
from 6 months to 81 years. Eleven additional serum samples acquired
prospectively from patients with febrile illness were obtained by the
LNS, Guatemala. Samples were frozen at−20 °C, stored for a maximum
of 1 week and then stored at−80 °C. Samples were then transported to
the UK for further testing. RNA samples were tested on the same day
with both assays and technicians were blinded to the results of other
tests to avoid bias.
3. Results
3.1. Assay characteristics and reproducibility
The linear range of the assay was 1 × 102 to 1 × 108 copies per reac-
tion, with an R2 value of 0.9998 over this range (Fig. 1). The efﬁciency of
the qRT-PCR was 0.98. The inter and intra assay coefﬁcient of variation
(CV) and average efﬁciency are shown in Table 1. The inter and intra
assay CV were 0.73% and 0.38%, respectively. The mean (SD) efﬁciency
of the PCR across the 5 experiments was 0.956 (0.02).
3.2. Limit of detection
The 95% LOD of the qRT-PCR was equivalent to 19.6 (95% CI:
14.3–29.6) copies of the target gene per assay, equating to 1.96 × 103
viral genomes per ml of serum. The 50% LOD was 10.6 (95% CI:
7.9–20.7) copies of the target gene per reaction. If a cut off of Ct 40
was used, the sensitivity increased and the 95% and 50% LOD were
17.7 (95% CI: 13.2–27.8) and 7.1 (95% CI: 5.2–16.6) copies of the target
gene respectively, with no apparent effect on speciﬁcity.
3.3. Speciﬁcity
The addition of non-target viral RNA did not result in a detectable
signal in the CHIKV qRT-PCR assay. Ampliﬁcation did not occur when
the 48 DENV-positive samples were tested. The primer and probe se-
quences were compared with sequences in the NCBI nucleotide data-
base and no non-target matches were found.ance of a Chikungunya qRT-PCR for Central and South America, Diagn
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Table 1
Average Ct, SD, and efﬁciency values are the average of 5 experiments containing 3 repli-
cates. SD, standard deviation; CV, coefﬁcient of variation.
cDNA equivalents/reaction
1 × 107 1 × 105 1 × 103
Average Ct 18.13133 24.958 31.86866667
Average SD 0.211689 0.106449 0.190857713
Inter assay CV 1.17% 0.43% 0.60%
Intra assay CV 1.15% 0.28% 0.46%
Overall results
Overall inter assay CV 0.73%
Overall intra assay CV 0.38%
Range of efﬁciency 0.93–0.98 (mean = 0.956)
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The CHIKV qRT-PCRwas positive in 63/64 of the samples positive by
the CDC qRT-PCR assay (sensitivity 98.4% [95% CI: 91.6–99.96%])
(Table 2). CHIKV ampliﬁcation was detected in the negative sample, at
a Ct 42. The Ct value obtained by the CDC assay was 36.52.
All 26 CDC qRT-PCR-negative samples were negative by the CHIKV
assay (speciﬁcity 100% [95% CI 86.77–100%]), with an overall agreement
of 98.9%.
3.5. Prospective samples
Three (27%) of 11 Guatemalan and 7 (11%) of 63 Ecuadorian pro-
spective samples were CDC qRT-PCR positive. The CHIKV qRT-PCR
assay identiﬁed 10/10 of the samples positive by the reference assay
(sensitivity 100%, 95% CI: 69–100%, Table 2). One of 64 CDC qRT-PCR-
negative samples was positive by the CHIKV qRT-PCR (speciﬁcity
98.4%, 95% CI: 92–99.9%), with an overall agreement of 98.6%. This dis-
cordant sample had a Ct value of 18with the index assay and no detect-
able ampliﬁcation with the CDC qRT-PCR.
3.6. Sequencing
Sequencing of the nsp4 gene of the discordant sample solely positive
by the index test identiﬁed two mismatches in the target region of the
forward CDC primer at positions 8 and 17 (5′ N 3′, GenBank accession
number KX296741). A further 5 randomly selected samples (ct b30)
from Guatemala were also sequenced, and the same base changes
were found to be present in each sample. Additionally, the nsp4 gene
of two samples from Ecuador were sequenced, and were both found
to carry one of the twomismatches, at position 8 of the forward primer.
The E1 gene of the above isolates was also sequenced (example:
KX296738), and no strains were found to have mismatches in the E1
primer or probe binding sites.
3.7. Internal control performance
There were no failures in the internal control in any of the 164 sam-
ples tested, allowing all samples to be included in the study. Mean (SD)
Ct values were 25.6 (0.53).Table 2
Diagnostic accuracy of the CHIKV qRT-PCR against the CDC qRT-PCR in bank and prospec-
tive specimens.
CHIKV E1 qRT-PCR CDC CHIKV qRT-PCR
Bank samples Positive (64) Negative (26)
Positive 63 0
Negative 1 26
Prospective samples Positive (10) Negative (64)
Positive 10 1
Negative 0 63
Please cite this article as: Edwards T, et al, Analytical and clinical perform
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The aim of this study was to design and perform a small evaluation
of a qRT-PCR assay capable of detecting all circulating lineages of
CHIKV. Central to this was the use of contemporary sequence data to
identify primer and probe binding sites that are highly conserved across
all CHIKV lineages. The ability to identify all CHIKV lineages is important
as returning travelers can instigate CHIKV outbreaks of strains from di-
verse geographical areas. Brazil, for example, reported outbreaks of the
Asian lineage, introduced via the Caribbean outbreak, and of the East
African strain, which is thought to have been introduced via a traveler
from Angola (Nunes et al., 2015).
The 95% Limit of Detection of our assay was 19.6 gene copies per re-
action, which, when combined with the QIAGEN Viral RNA extraction
kit, and assuming 100% efﬁciency in each step of the process, equates
to 1.96 × 103 genome copies/ml of sample. This is over a hundred fold
lower than themean viraemia of 5.6× 105 and 3.4 × 103 plaque forming
units (PFU)/ml reported in laboratory conﬁrmed symptomatic and
asymptomatic CHIKV cases in Thailand (Appassakij et al., 2013). The
LOD of our assay lies over one log10 below the range of the viral titres
reported in the Caribbean (Charles et al., 2015; Gallian et al., 2014)
and is comparable to reported CHIKV qRT-PCR assays reporting LODs
ranging from 5.3 to 27 RNA copies per reaction (Santiago et al., 2013).
The linear range of the assay spanned 102 to 108 copies of viral RNA
per reaction, with an R2 value of 0.9998 indicating excellent linearity.
The assay was also highly reproducible. These factors allow the use of
the assay as a quantitative tool (Peixoto et al., 2004), when paired
with a standard curve of known target concentration.
The single discordant sample among the retrospective samples had a Ct
of 36.5 in the reference assay, whilst our assay ampliﬁed the RNA over the
Ct 37 threshold. The mean (SD) Ct values obtained using the CDC assay
were lower (22.41, SD6.67) thanour CHIKVassay (24.34, SD6.67), possibly
due to the inclusion of an internal control assay reducing ampliﬁcation efﬁ-
ciency, or differences in the reaction mix reagents used for the two assays.
The index PCR reported a single CDC PCR-negative sample as positive,
resulting in a speciﬁcity of 98.4% (95% CI: 92–99.9%). This sample had a
particularly low Ct, indicating a copy number of 2.2 × 107 copies per reac-
tion, equating to 2.2 × 109 viral genomes perml. The detection of two sep-
arate CHIKV genes through sequencing indicates that CHIKV RNA was
likely present in the sample, and this positive result is unlikely to be due
to lack of speciﬁcity. The sequence of the target of reference PCR included
two mismatches in the forward primer of this assay, which could poten-
tially have led to the failure to amplify. However, sequencing of ﬁve refer-
ence PCR positive samples from Guatemala also found these same
mismatches in all samples, indicating that they alone do not prevent PCR
ampliﬁcation. The Ct values obtained for the CDC assay were lower
(mean−0.96) than those obtained using the E1 assay, demonstrating no
apparent loss in ampliﬁcation efﬁciency due to the mismatches. Subse-
quent analysis of this region in sequence data submitted to GenBank
showed these two mutations to be present in the majority of Asian
CHIKV strains introduced into the Americas via the Caribbean outbreak.
Example sequences include KY703993.1 (Nicaragua, 2014), KY680370.1
(USA, 2014) KT327165.2 (Mexico 2014) KR559495.1 (Puerto Rico, 2014)
and Brazil (KP164567.1). Notably these mutations were absent in the
ECSA origin strains thatwere introduced into Brazil in 2014 (KP164570.1).
Mutations in primer binding sites are an inevitable issue in the use of
molecular diagnostics, especially in highly mutable RNA viruses. These
mutations can cause lower binding efﬁciency, resulting in reduced sensi-
tivity and inaccurate quantiﬁcation and possibly result in false negative
results, as reported for a diverse range of viral targets, including Eastern
Equine Encephalitis, herpes simplex and avian inﬂuenza (Armstrong
et al., 2012). Frequent update of assays via the incorporation of contempo-
rary strains in the design process is necessary to negate this variation.
The validation of the assay was carried out using samples collected
in Guatemala and Ecuador in July and August 2015, which solely includ-
ed strains descended from the Asian strain responsible for the Centralance of a Chikungunya qRT-PCR for Central and South America, Diagn
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ment was obtained from cultivated ESCA strain CHIKV; however, no
clinical ESCA,West African or Asia-circulating Asian strains were tested,
and further evaluationwould be required to determine theperformance
of the assay with these strains.
The study included a small scale clinical evaluation, and furtherwork
including a greater number of more diverse samples is required to eval-
uate the performance of the assay in more detail.
5. Conclusion
We describe the design and evaluation of a Taqman based real-time
qRT-PCR assay for the detection of CHIKV via the ampliﬁcation of an
110 bp fragment of the E1 gene. The assay has comparable sensitivity
and speciﬁcity to the CDC CHIKV qRT-PCR. The 95% and 50% LOD were
estimated as 19.6 and 10.6 copies per reaction, respectively.
The qRT-PCR assay detailed here has undergone a robust analytical
evaluation to determine the most important aspects of assay perfor-
mance to provide a high level of conﬁdence in its application for diag-
nosing acute CHIKV infection. The assay has been designed to detect
all lineages of CHIKV, with particular focus on the strains causing the
current outbreaks in South America. The assay evaluation has been re-
ported according to STARD 2015 reporting guideline for diagnostic ac-
curacy studies, as supported by the supplementary STARD checklist.
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